Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.

Friday, January 2, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+

ALISO VIEJO, Calif., Jan. 2 ValeantPharmaceuticals International (NYSE: VRX) today announced that effectiveDecember 31, 2008, the company completed its acquisition of Dow PharmaceuticalSciences, Inc., a privately held dermatology company that specializes in thedevelopment of topical products on a proprietary basis, as well as forpharmaceutical and biotechnology companies.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinationalspecialty pharmaceutical company that develops, manufactures and markets abroad range of pharmaceutical products primarily in the areas of neurology anddermatology. More information about Valeant can be found athttp://www.valeant.com.(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO) Contact: Laurie W. Little Valeant Pharmaceuticals 949-461-6002

SOURCE Valeant Pharmaceuticals International


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store